No differences seen in the rates of major adverse CV events (MACE) between RA, axial SpA or PsA pts, suggesting inflammation, rather than a disease, drives CV risk. Data from a Swiss mixed retrospective/prospective cohort study https://t.co/Kn8a8tWId9